DRugwatch BlogRSS 2.0

DRugwatch Blog > April 2013 > A CHMP Decision for Belviq is Coming Soon—High Stakes for Arena, But Will It Matter?

A CHMP Decision for Belviq is Coming Soon—High Stakes for Arena, But Will It Matter?

Rob DubmanContributor: Donny Wong

While America waits for Arena and Eisai to finally get the green light from the FDA and the DEA to begin marketing the weight-loss drug Belviq (lorcaserin), Arena shareholders and European patients are waiting with bated breath for a nod from the CHMP, which will pave the way for the European Medicines Agency to approve marketing authorization for Belviq.

The various investor boards are buzzing about how vital a European approval for Belviq would be for Arena. And you cannot argue that point, since it is important for every company to increase its market potential by extending the geographical reach of its products. But here’s why I think it’s not going to matter too much to Arena’s bottom line even if Belviq does not gain European marketing authorization: very few patients will be able to receive the drug. Am I talking about low prescriptions, poor reimbursement or reluctance of patients to pay out of pocket? Yes, I am talking about all of these issues, which together will mean very few patients will receive Belviq.

The demand for obesity drugs is certainly high in Europe. Decision Resources epidemiologists estimate the obesity prevalence in the United Kingdom, which has the dubious honor of being the fattest nation in Europe, to be as high as 26% among the adult population. More worrying is the 38% of the UK population that is clinically overweight, as a sizeable proportion of the overweight population will slide into the obese category in the coming years. Germany is not far behind, followed by Spain and France. All of us in Europe are following America’s lead as one of the fattest nations on earth—where 37% of the adults are clinically obese and another 33% are overweight. (And yes, you read this correctly. Since 2009, the U.S. has had more obese than overweight adults—a sobering fact considering the long-term cost burden of obesity.)

And so it is no wonder that Belviq is generating a lot of buzz. In fact, because so few drugs have been approved for obesity over the past few decades, each green light from the regulatory agencies is a cause for celebration. We were treated to two FDA approvals in 2012—for Belviq and Vivus’s Qsymia (phentermine + topiramate). And while it no longer looks like Qsymia has any chance of approval in Europe following Vivus’s unsuccessful appeal, there is still hope for Belviq. Investors are salivating at the potential for Belviq in Europe, especially since there is no significant competition (Roche’s Xenical is the only prescription weight-loss drug currently available in Europe, following the withdrawal of Abbott’s Meridia, Servier’s Mediator, and Sanofi’s Acomplia over the past few years).

So here’s my take on why very few patients will receive Belviq (and why sales figures will be low in Europe).

  • Belviq might be safe enough to merit approval, but it falls short in terms of weight-loss efficacy. Newly published data from a primary market research survey authored by Decision Resources show that an obesity drug needs to elicit a minimum 6-10% mean weight-loss efficacy before physicians will consider prescribing it. However, the sweet spot is 11-15% average weight loss, at which point a sizeable proportion of prescribers will put patients on a drug. At just 4-5% placebo-adjusted weight loss, Belviq falls short of these thresholds. In fact, even Qsymia falls slightly short of the second level of expectation, at roughly 9-10% placebo-adjusted weight loss. Although these data are for U.S. prescribers, we can infer that European prescribers probably share similar expectations.

  • The true potential for Belviq is as an add-on therapy for phentermine. However, in our survey (see graphic below), a sizeable proportion of U.S. endocrinologists are reluctant to prescribe such a combination, even if it is approved by the FDA (due in part to memories of the Fen-Phen debacle from the mid-1990s). The proportion of physicians who would prescribe Belviq together with phentermine increases by 50% if the FDA approved the two drugs for combination use, however this would make no impact on European sales, since phentermine is not marketed in Europe (and there is no indication that it will become widely available there any time soon).

  • Our survey data show that we can expect poor reimbursement coverage by commercial and Medicare plans in the U.S. based on the proposed $200/month ($6.67/day) price point for Belviq, with many health plans intending to exclude coverage for Belviq altogether. This means that many U.S. patients will have to pay fully out-of-pocket for the drug. In the major European markets, we similarly expect that there will continue to be no reimbursement for obesity drugs, so most patients will have to pay out of pocket for Belviq. And whether you are counting in pounds or euros, I don’t think many folks are going to pay the equivalent of $6.67/day for the chance of losing an average of 4% of their body weight.


Physician & Payer Forum Survey



Donny Wong, Ph.D., is Senior Director of Cardiovascular and Metabolic Disorders at Decision Resources, based in London, United Kingdom. His research, analyses and commentaries have appeared in numerous media outlets, including the Wall Street Journal, Barron’s, Pharmaceutical Executive, Forbes and BBC America.
Posted on: 4/8/2013 6:52:02 PM | with 0 comments


Tags: Donny Wong, Metabolic Disorders

Trackback URL: http://decisionresources.com/trackback/1baee79d-1a75-4c5d-af22-cdc49f022ec2/A-CHMP-Decision-for-Belviq-is-Coming-Soon—High-Stakes-for-Arena,-But-Will-It-Matter-.aspx?culture=en-us

Comments
Blog post currently doesn't have any comments.
Leave comment Subscribe



What is the abbreviation for Accountable Care Organization?

 

rss twitter linkedin

 

DRugwatch Blog

Quick insight on intriguing drug market developments from Decision Resources’ analysts.

Recent posts

Post title:
2015 ESC Congress in London – Overview of Upcoming Hot Line Sessions
Post date:
7/2/2015 11:57:46 PM
Post Summary:
Conor WalshContributor: Conor Walsh M.Sc., Ph.D.
Topics: Conference Commentary, Cardiovascular

This year’s ESC congress will take place in the Excel Exhibition Centre in London, United Kingdom. The spotlight this year is “environment and the heart,” highlighting the many different kinds of interactions between the environment and cardiovascular diseases.

Post title:
FDA Approval for The Medicines Company’s Intravenous Antiplatelet Kengreal
Post date:
6/23/2015 1:22:54 PM
Post Summary:
Conor WalshContributors: Conor Walsh, M.Sc., Ph.D.
Topics: Cardiovascular

On June 22nd, 2015 the U.S. FDA approved Kengreal (cangrelor), the Medicines Company’s intravenous antiplatelet drug for use “as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.”

Post title:
Hematological Malignancies: Are Immune Checkpoint Inhibitors Checking-in?
Post date:
6/17/2015 9:32:42 AM
Post Summary:
Contributor: Dana Gheorghe, Ph.D
Topics
: Conference Commentary, Oncology


Recent years have seen an added emphasis on the relationship between cancer and the activity of the immune system. Novel agents that aim to harness the immune system have already been approved in the U.S. for solid tumors (Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo [nivolumab] for NSCLC and malignant melanoma, and Merck & Co.’s Keytruda [pembrolizumab] for malignant melanoma), and are in development for a plethora of other oncology indications. Most of the development has been targeted towards solid tumors, but the potential of immune checkpoint inhibitors in hematological malignancies is becoming increasingly evident.

Post title:
Cardiovascular Outcomes Trials Answer Long-Asked Questions – But New Questions Arise
Post date:
6/12/2015 10:26:05 AM
Post Summary:
Contributor: Eamonn O'Connor, Ph.D.

The recent American Diabetes Association’s 75th Scientific Sessions in Boston saw the release of data from the ELIXA cardiovascular outcomes trial (CVOT) for lixisenatide (Sanofi/Zealand Pharma’s Lyxumia), the first such trial completed for the GLP-1 receptor agonist drug class. However, it was the publication of the data from the CVOT for sitagliptin (Merck’s Januvia/Ono’s Glactiv), known as TECOS1, that was most eagerly anticipated; this is because the previous CVOTs for saxagliptin (AstraZeneca’s Onglyza) and alogliptin (Takeda/Furiex’s Nesina/Vipidia) had raised significant concerns about a potential risk for increased rates of hospitalization due to heart failure. The results from TECOS therefore, were viewed as pivotal as to whether this risk was a feature specific to the DPP-IV inhibitor drug class.

Post title:
Malignant Melanoma: Evolving Standards of Care
Post date:
6/5/2015 2:52:20 PM
Post Summary:
Contributor: Natalia Reoutova, M.Sc.
Topics: Conference Commentary, Oncology

The past five years have seen unprecedented progress in the treatment of malignant melanoma, which translated into approval of highly efficacious immunotherapies, targeted small-molecule therapies, and several combination regimens.

Decision Resources Group brands include: